home / stock / nvo / nvo news

NVO News and Press, Novo Nordisk A/S From 05/22/24

Stock Information
Company Name: Novo Nordisk A/S
Stock Symbol: NVO
Market: NYSE
Website: novonordisk.com
Menu
NVO NVO Quote NVO Short NVO News NVO Articles NVO Message Board
Get NVO Alerts

News, Short Squeeze, Breakout and More Instantly...
NVO - FDA reviewers voice concerns over hypoglycemia with Novo Nordisk weekly insulin

2024-05-22 11:25:25 ET More on Novo Nordisk The FTC Cracks Down On Novo Nordisk's Ozempic Novo Nordisk A/S 2024 Q1 - Results - Earnings Call Presentation Novo Nordisk A/S (NVO) Q1 2024 Earnings Call Transcript Novo Nordisk office building fire brought under c...
NVO - NeuroBo says DA-1241, Wegovy combo shows potential in treating MASH

2024-05-22 10:01:06 ET More on NeuroBo Pharmaceuticals NeuroBo Phase 2a study for MASH drug to proceed as planned NeuroBo stock jumps 14% on weight-loss drug update Seeking Alpha’s Quant Rating on NeuroBo Pharmaceuticals Historical earnings data for Ne...

NVO - Novo Nordisk hit by a second fire within a week

2024-05-22 08:13:08 ET More on Novo Nordisk The FTC Cracks Down On Novo Nordisk's Ozempic Novo Nordisk A/S 2024 Q1 - Results - Earnings Call Presentation Novo Nordisk A/S (NVO) Q1 2024 Earnings Call Transcript Australia to ban copycat versions of weight loss ...

NVO - Hims & Hers cut to Neutral at Citi on recent rally

2024-05-22 07:51:38 ET More on Hims & Hers Health Hims & Hers: Soaring On Access To Compounded GLP-1 Drugs, Further Volatility Ahead 10 Solid Reasons To Buy Hims & Hers Stock Hims & Hers: Strong Operating Leverage And Profitability Inflection ...
NVO - Australia to ban copycat versions of weight loss drugs like Ozempic

2024-05-22 07:14:37 ET More on Eli Lilly, Novo Nordisk, etc. Eli Lilly: Great Time To Divest Before It Potentially Crashes Eli Lilly Remains Expensive Here - Minimal Margin Of Safety The FTC Cracks Down On Novo Nordisk's Ozempic Study finds 30% of Wegovy, Sax...

NVO - Study finds 30% of Wegovy, Saxenda users quit within 4 weeks

2024-05-21 14:06:23 ET More on Novo Nordisk The FTC Cracks Down On Novo Nordisk's Ozempic Novo Nordisk A/S 2024 Q1 - Results - Earnings Call Presentation Novo Nordisk A/S (NVO) Q1 2024 Earnings Call Transcript Novo Nordisk unsure when it will meet obesity dru...

NVO - Novo Nordisk unsure when it will meet obesity drug demand: report

2024-05-21 11:50:45 ET More on Novo Nordisk The FTC Cracks Down On Novo Nordisk's Ozempic Novo Nordisk A/S 2024 Q1 - Results - Earnings Call Presentation Novo Nordisk A/S (NVO) Q1 2024 Earnings Call Transcript Microcap Mangoceuticals doubles on plan to sell c...
NVO - Roundhill Investment launches GLP-1 & Weight Loss ETF

2024-05-21 10:29:09 ET More on Weight Loss Drugs Hims & Hers: Soaring On Access To Compounded GLP-1 Drugs, Further Volatility Ahead Genetics may determine who responds well to Wegovy: report One in eight U.S. adults admits to GLP-1 usage as public aware...

NVO - Microcap Mangoceuticals doubles on plan to sell cheap oral GLP-1 weight loss meds

2024-05-21 09:21:57 ET More on Eli Lilly, Novo Nordisk Eli Lilly: Great Time To Divest Before It Potentially Crashes Eli Lilly Remains Expensive Here - Minimal Margin Of Safety The FTC Cracks Down On Novo Nordisk's Ozempic Eli Lilly inks radiopharma deal wort...

NVO - Eli Lilly's tirzepatide cleared for diabetes treatment in China

2024-05-21 06:43:02 ET Eli Lilly ( NYSE: LLY ) has secured China approval for its blockbuster drug tirzepatide for use in treating diabetes.... Read the full article on Seeking Alpha For further details see: Eli Lilly’s tirzepatide cleared for diabetes treatme...
Previous 10 Next 10